Esteve-Pastor M.A.,University of Murcia |
Esteve-Pastor M.A.,Instituto Murciano Of Investigacion Biosanitaria Virgen Of La Arrixaca Imib |
Roldan V.,Instituto Murciano Of Investigacion Biosanitaria Virgen Of La Arrixaca Imib |
Roldan V.,University of Murcia |
And 6 more authors.
Expert Review of Cardiovascular Therapy | Year: 2016
Oral anticoagulation therapy is essential in patients with atrial fibrillation and clinicians need guidance on decision-making between the vitamin K antagonists (VKA), e.g. warfarin, or non-vitamin K antagonist oral anticoagulants. Observational studies have shown that patients who receive VKA therapy spend a significant percentage of their time with international normalized ratio values outside of the therapeutic range (time in therapeutic range, TTR <60%.) Recently, a clinical score has been developed with commonly encountered clinical features, the SAMe-TT2R2 score, to help decision-making with regard to whether a patient is likely to do well, or not, with a VKA. Those with a SAMe-TT2R2 score of 0-1 are likely to do well on a VKA, while those with a SAMe-TT2R2 score ≥2 are on probability going to achieve suboptimal TTR. In this article, we provide an overview of the main published retrospective and prospective studies that have validated the SAMe-TT2R2 score and its value for decision-making in daily clinical practice. © 2015 Taylor & Francis.